Amneal launches new biosciences unit
Amneal Pharmaceuticals has launched Amneal Biosciences, a wholly owned subsidiary. Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.
“Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to healthcare institutions and professionals that we deliver to our existing retail customers,” said Amneal Co-CEO and Chairman Chirag Patel. “Amneal has a robust pipeline of both small-molecule injectable generics as well as biosimilars, and we expect to bring the first of these to market in early 2016.”
Heading Amneal Biosciences as president is pharmacy veteran Charles Lucarelli, M.S., R.Ph. Lucarelli joined Amneal in March after a 37-year career at Memorial Sloan-Kettering Cancer Center, including 25 years as director of pharmacy.
Amneal is privately held with U.S. headquarters in Bridgewater, N.J., and international headquarters in Zug, Switzerland.